Genome Canada Financial Support Boosts ClarityDX Prostate Testing Across Canada

Major Investment in Prostate Cancer Diagnostics



On June 26, 2025, Nanostics Inc., a leader in precision health, announced a substantial financial backing from Genome Canada and Genome Alberta. This funding aims to enhance the integration of the ClarityDX Prostate test into the standard prostate cancer screening protocols across Canada. The investment is a part of the Canadian Biotechnology Innovation and Commercialization Initiative (CBIC), marking a significant step towards innovative cancer diagnostics in the country.

Background of ClarityDX Prostate



ClarityDX Prostate is a laboratory-developed test that employs machine learning algorithms to enhance the accuracy of prostate cancer screening. By analyzing clinical and blood-based biomarker data, this test predicts the risk associated with aggressive prostate cancers. Currently, it operates under a patient-pay model, but the new funding seeks to transition it into a universally accessible service that Canadian men can rely on during screenings.

Led by Dr. John Lewis, the Bird Dogs Chair in Translational Oncology at the University of Alberta, this initiative encompasses collaborations among academia, clinical institutions, and economic entities to ensure comprehensive integration within Alberta's healthcare system first. Subsequently, it aims to extend across Canada, offering a more efficient and responsive healthcare experience for those dealing with prostate cancer.

The Objectives of the Investment



The core aim of this initiative is to compile a robust evidence package that manifests the clinical efficacy and economic advantages of implementing the ClarityDX Prostate test within the country's diagnostic pathway. Success in this realm could pave the way for reimbursement from healthcare providers, thus improving public accessibility.

The comprehensive evidence package will include:
  • - Clinical Utility Study: Demonstrating the practical performance of the ClarityDX Prostate test in real-world settings.
  • - Health Impact Feasibility Study: Assessing potential health outcomes associated with its widespread adoption.
  • - Health System Integration Study: Analyzing the impact on and the integration within the current health care framework in Alberta and beyond.

Collaborative Efforts for Better Health Outcomes



Dr. John Lewis expressed his profound gratitude for Genome Canada's belief in this project and how it would accelerate the adoption of the ClarityDX Prostate test. He emphasized that this collaboration with Acute Care Alberta is a step toward enhancing the outcomes for men throughout their screening and diagnostic journey. Tara Klassen, Ph.D., innovation lead for Surgical Care Alberta, echoed this sentiment, stating that this cooperation exemplifies a united effort to provide the highest quality healthcare to Albertans.

Ordering ClarityDX Prostate



For those interested in obtaining the ClarityDX Prostate test, it is accessible throughout Canada (excluding Quebec). Interested parties can visit Nanostics to initiate their order. In Quebec, inquiries can be directed to CDL Laboratories. For those in the United States, the test is available through Protean BioDx.

About Nanostics Inc.



Nanostics Inc. is a private Canadian firm focused on developing innovative, non-invasive diagnostic solutions. The company's flagship product, ClarityDX, is tailored not only for prostate cancer but also for a broader spectrum of health challenges, leveraging advanced machine learning algorithms to generate disease risk scores. With a vision for improved diagnostic accuracy, Nanostics continues to invest in research and development. Visit Nanostics for further details and updates.

Through these efforts, the ClarityDX Prostate test stands poised to revolutionize prostate cancer screening, ensuring that men across Canada have access to vital diagnostic tools that can influence their health outcomes positively.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.